<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000450</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAMAS10518</org_study_id>
    <secondary_id>R01AA010518</secondary_id>
    <nct_id>NCT00000450</nct_id>
  </id_info>
  <brief_title>Naltrexone Maintenance Treatment of Alcoholism</brief_title>
  <official_title>Nalmefene Maintenance Treatment of Alcoholism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Scripps Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The Scripps Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the long-term effectiveness of naltrexone treatment&#xD;
      in alcohol-dependent patients who respond to short-term treatment. Those who respond to&#xD;
      short-term treatment will be randomized to a 1-year, double-blind, placebo-controlled&#xD;
      maintenance phase with a 6-month posttreatment followup.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 1997</start_date>
  <completion_date type="Actual">February 13, 2002</completion_date>
  <primary_completion_date type="Actual">February 13, 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Naltrexone 50 mg was provided for 3 months to all study participants, who were masked regarding the identity of study medication. At 3 months, full and partial responders were randomized to an additional 9 months of double blind treatment with naltrexone or matched placebo. Full responders were defined as complete abstinence for the last six weeks of the acute phase. Partial responders were defined as having no more than 2 heavy drinking days in any given week and/or a 50% reduction in weekly alcohol consumption from baseline over the last six weeks of the acute phase.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Naltrexone and placebo were identical in appearance and packaging to preserve the double blind.</masking_description>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Alcoholism</condition>
  <arm_group>
    <arm_group_label>Naltrexone Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Placebo Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone Tablet</intervention_name>
    <arm_group_label>Naltrexone Tablet</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebo Tablet</intervention_name>
    <arm_group_label>Matched Placebo Tablet</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meets criteria for alcohol dependence.&#xD;
&#xD;
          -  Expresses a desire to cut down or stop drinking.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently meets criteria for dependence on substances other than alcohol.&#xD;
&#xD;
          -  History of opiate dependence or evidence of current opiate use.&#xD;
&#xD;
          -  Significant medical disorders that will increase potential risk or interfere with&#xD;
             study participation.&#xD;
&#xD;
          -  Liver function tests more than 3 times normal or elevated bilirubin.&#xD;
&#xD;
          -  Female patients who are pregnant, nursing, or not using a reliable method of birth&#xD;
             control.&#xD;
&#xD;
          -  Inability to understand and provide a consent form.&#xD;
&#xD;
          -  Treatment with an investigational drug during the previous month.&#xD;
&#xD;
          -  Prior treatment with naltrexone.&#xD;
&#xD;
          -  Chronic treatment with any narcotic-containing medications during the previous month.&#xD;
&#xD;
          -  Sensitivity to naltrexone as evidenced by adverse drug experiences especially with&#xD;
             narcotic containing analgesics or opioid antagonists.&#xD;
&#xD;
          -  Current treatment with disulfiram.&#xD;
&#xD;
          -  More than 6 weeks of abstinence.&#xD;
&#xD;
          -  Meets criteria for a major psychiatric disorder and is in need of, or currently&#xD;
             undergoing pharmacotherapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Mason, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Scripps Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>November 2, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 1999</study_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Scripps Research Institute</investigator_affiliation>
    <investigator_full_name>Barbara J. Mason</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

